Post-Hoc Analyses of Phase 3 ARCHES Trial: OS in Patients With mHSPC Who Received Prior ADT and Reached Low PSA Levels Treated Further With Enzalutamide

665 views
December 16, 2022
Comments 0
Login to view comments. Click here to Login